Notch Signaling Components

Liu, Zhiyan; Wu, Tao; Li, Qing; Wang, Mincong; Li, Jing; Ruan, Zhiping; Yao, Yu; Kang, Nan; Guo, Hui

doi:10.1097/md.0000000000003715

Cited by 19 publications

(12 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[28,29] Furthermore, our literature search and review showed that DLL3 expression was not associated with any survival significance of patients with small-cell lung cancer but that elevated DLL3 expression was associated with poor overall survival of patients with lung adenocarcinoma, but not of patients with lung squamous cell carcinoma and with poor overall survival of patients with nonsmall-cell lung cancer. [39,44,45] Thus, our present data on the association of DLL3 overexpression with reduced overall survival of patients with endometrial cancer are consistent with that of the lung adenocarcinoma study.…”

Section: Discussionsupporting

confidence: 89%

Upregulated delta-like protein 3 expression is a diagnostic and prognostic marker in endometrial cancer

Wang¹,

Zhang²,

Li³

et al. 2018

Medicine

View full text Add to dashboard Cite

Upregulated delta-like protein 3 (DLL3) functions as a Notch ligand and has been a target for cancer therapy. The present study assessed DLL3 expression as a tumor marker for endometrial cancer.RNA-Seq expression data and clinicopathologic records from 545 patients with endometrial cancer were downloaded from The Cancer Genome Atlas database. Mann–Whitney U and logistic regression tests were applied to associate the level of DLL3 expression with clinical variables from the patients. Kaplan–Meier curves and log-rank tests were performed to compare overall survival of patients stratified by different levels of DLL3 expression. Multivariate Cox regression tests were used to analyze independent predictors for endometrial cancer. DLL3 expression was upregulated in endometrial cancer tissues compared to para-carcinoma tissues (P = .0003). High DLL3 expression was associated with the age of patients (odds ratio [OR] = 1.74), advanced stages of the International Federation of Gynecology and Obstetrics system (OR = 2.9), grade III/IV (OR = 5.1), myometrial invasion (OR = 2.2), pelvic involvement (OR = 12.9), and para-aortic lymph node metastasis (OR = 9.9) (all P ≤ .001). Furthermore, upregulated DLL3 expression was also associated with a median overall survival of 112 months (HR = 1.85, confidence internal 1.202–2.846, P = .005). The multivariate analysis showed that DLL3 overexpression and advanced tumor stages, grades, and lymph node metastases were all independent prognostic predictors for endometrial cancer.The DLL3 expression could be a potential and novel tumor marker for early diagnosis and an independent predictor of poor survival for patients with endometrial cancer.

show abstract

Section: Discussionsupporting

confidence: 89%

Upregulated delta-like protein 3 expression is a diagnostic and prognostic marker in endometrial cancer

Wang¹,

Zhang²,

Li³

et al. 2018

Medicine

View full text Add to dashboard Cite

show abstract

“… 19 The database was used as previously described. 20 Briefly, the genes were entered into the database of GC to obtain Kaplan–Meier survival plots. The Multivariate Cox regression model was used and HR, 95% CI, and log-rank p -value were calculated and displayed.…”

Section: Methodsmentioning

confidence: 99%

Expression and clinical significance of autophagic protein LC3B and EMT markers in gastric cancer

Wang

Wu²,

et al. 2018

CMAR

Self Cite

View full text Add to dashboard Cite

Background and aimGastric cancer (GC) is a fatal malignancy with high rate of recurrence and metastasis. Here, we investigated the correlations between the expression of autophagic protein LC3B and 2 epithelial–mesenchymal transition-related proteins (E-cadherin and Vimentin) and the clinicopathological factors and prognosis of patients with GC.Materials and methodsThe expression of LC3B, E-cadherin, and Vimentin in GC samples (110 cases) and paracarcinoma tissues (40 cases) was analyzed using the Oncomine databases and further detected by immunohistochemistry. The correlations among these markers expression and clinicopathological features in GC were analyzed. The patients were followed for survival analysis.ResultsCompared to the nontumor tissues, the expression of LC3B and Vimentin proteins were significantly elevated in GC tissues, but the E-cadherin expression was decreased (all p<0.05). Interestingly, LCB expression was positively correlated with Vimentin (r=0.320, p=0.001) and negatively associated with E-cadherin expression (r= −0.484, p<0.001) in GC. The expression of these markers was closely related to tumor differentiation, T classification, TNM stage, and lymph node metastasis (all p<0.05). Furthermore, survival analyses and screening Kaplan–Meier plotter database revealed that GC patients with high LC3B and Vimentin expression levels had a poorer clinical outcome than those with low expression. Conversely, high E-cadherin expression was linked with favorable overall survival (all p<0.05, log-rank test). Multivariate survival analysis demonstrated that LC3B, E-cadherin, and Vimentin expression were independent prognostic factors of GC patients.ConclusionLC3B, E-cadherin, and Vimentin may play an important role in the tumorigenesis of GC, and these marker expressions may serve as additional prognostic indicators for overall survival of patients. The interactions of autophagy and epithelial–mesenchymal transition in GC merits further investigation.

show abstract

“…25 High DLL3 expression predicts poor overall survival (OS) in lung adenocarcinoma, playing an opposing prognostic role to DLL1. 26 In high-grade neuroendocrine lung tumors (including small cell lung cancer (SCLC) and large-cell neuroendocrine cancer (LCNEC)), DLL3 is overactive at the tumor cell surface and positively correlates with achaete-scute homolog-1 (ASCL1), a member of the BHLH family of transcription factors that is involved in neuroendocrine cell fate decisions. [27][28][29] ASCL1 activates DLL3 by binding to special E-box sites in the DLL3 promoter, as observed in the dorsal neural tube.…”

Section: Delta-like Ligands In Lung Cancermentioning

confidence: 99%

<p>The Role of DLLs in Cancer: A Novel Therapeutic Target</p>

Xiu

Liu

Kuang

2020

OTT

View full text Add to dashboard Cite

Delta-like ligands (DLLs) control Notch signaling. DLL1, DLL3 and DLL4 are frequently deregulated in cancer and influence tumor growth, the tumor vasculature and tumor immunity, which play different roles in cancer progression. DLLs have attracted intense research interest as anti-cancer therapeutics. In this review, we discuss the role of DLLs in cancer and summarize the emerging DLL-relevant targeting methods to aid future studies.

show abstract

Notch Signaling Components

Abstract: Supplemental Digital Content is available in the text

Cited by 19 publications

References 52 publications

Upregulated delta-like protein 3 expression is a diagnostic and prognostic marker in endometrial cancer

Upregulated delta-like protein 3 expression is a diagnostic and prognostic marker in endometrial cancer

Expression and clinical significance of autophagic protein LC3B and EMT markers in gastric cancer

<p>The Role of DLLs in Cancer: A Novel Therapeutic Target</p>

Contact Info

Product

Resources

About